Clinical Trial Update: Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nimotuzumab in combination with immune checkpoint inhibitors for advanced hepatocellular carcinoma after first-line treatment …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: HCC | Phase 2 | Status: RECRUITING